Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 1,453 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 1,453 shares of the firm's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total value of $79,682.52. Following the sale, the chief operating officer now directly owns 196,594 shares of the company's stock, valued at $10,781,214.96. This trade represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, June 10th, Jonathan Young sold 2,493 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.99, for a total transaction of $134,597.07.

Akero Therapeutics Price Performance

NASDAQ:AKRO traded down $0.70 on Friday, reaching $54.20. The stock had a trading volume of 1,983,828 shares, compared to its average volume of 1,019,471. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $4.32 billion, a P/E ratio of -27.79 and a beta of -0.16. Akero Therapeutics, Inc. has a 1-year low of $21.02 and a 1-year high of $58.40. The stock has a fifty day moving average price of $45.88 and a 200-day moving average price of $41.10.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. Research analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors have recently bought and sold shares of the business. RTW Investments LP grew its holdings in shares of Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Deep Track Capital LP lifted its position in Akero Therapeutics by 116.0% during the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after buying an additional 800,216 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Akero Therapeutics during the 4th quarter worth about $18,059,000. SG Americas Securities LLC grew its holdings in Akero Therapeutics by 93.3% during the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after acquiring an additional 557,794 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in Akero Therapeutics in the 1st quarter valued at about $21,333,000.

Analyst Ratings Changes

AKRO has been the topic of a number of recent research reports. Citigroup cut their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, Bank of America raised their price objective on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.